en · de · es · fr · pt
sr9009-notes.peptides9000.com › Data › Handling, Analysis, And Regulation — Complete Guide

Handling, Analysis, And Regulation — Complete Guide

By Editorial Desk · published 2026-07-09 · last reviewed 2026-08-01 · Data

research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Handling, Analysis, and Regulation

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.

SR9009 Identity and Mechanism

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

Sr9009 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderCommon supplier description
SolubilitySoluble in DMSO and ethanolLow solubility in water
Typical storage−20 °C, desiccated, darkFor research samples
Analytical methodLC-MS/MSUsed for detection and quantification
Regulatory statusProhibited in sportWADA metabolic modulator class

Handling Storage and Quality Control

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Related pages on this site

Mechanism and Preclinical Findings

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

Identity, Handling, and Regulation

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Further detail

Among other things, the parathyroid hormone causes calcium and phosphate to be released from the bones, which ultimately leads to renal bone disorders and calcification of the kidneys, skin, heart and blood vessels. In the kidneys, this calcification contributes to further destruction of the kidney tissue. The reduced responsiveness of the parathyroid cells to calcium disrupts the negative feedback of parathyroid hormone secretion, so that parathyroid hormone continues to be secreted despite the increase in calcium levels. As less phosphate reaches the renal tubules due to the reduced filtration rate, the inhibitory effect of parathyroid hormone on reabsorption in the main body has only a minor effect on the blood phosphate level. The loss of nephrons and the associated decrease in the number of sodium ion channels leads to a decrease in the concentration gradient in the kidney. However, this is the driving force for water reabsorption in the mid-piece and—in the presence of ADH—also in the collecting ducts. The result is a loss of water via the urine and thus drying out of the body, which is exacerbated by the loss of fluid during vomiting. One consequence of the kidneys' reduced ability to excrete hydrogen ions, phosphate and sulphate and the excessive loss of bicarbonate is the metabolic acidification of the blood (metabolic acidosis). Metabolic acidosis occurs in 80% of cats with chronic kidney disease.

== Chemistry == Buserelin is a GnRH analogue, or a synthetic analogue of GnRH. It is a nonapeptide and is also known as [D-Ser(tBu)6,des-Gly-NH210]GnRH ethylamide or as D-Ser(tBu)6EA10-GnRH. Buserelin is marketed for medical use in both its free base (buserelin) and acetate salt (buserelin acetate) forms.

Another fissile isotope, uranium-233, can be produced from natural thorium and is studied for future industrial use in nuclear technology. Uranium-238 has a small probability for spontaneous fission or even induced fission with fast neutrons; uranium-235, and to a lesser degree uranium-233, have a much higher fission cross-section for slow neutrons. In sufficient concentration, these isotopes maintain a sustained nuclear chain reaction. This generates the heat in nuclear power reactors and produces the fissile material for nuclear weapons. The primary civilian use for uranium harnesses the heat energy to produce electricity. Depleted uranium (238U) is used in kinetic energy penetrators and armor plating. The 1789 discovery of uranium in the mineral pitchblende is credited to Martin Heinrich Klaproth, who named the new element after the recently discovered planet Uranus. Eugène-Melchior Péligot was the first person to isolate the metal, and its radioactive properties were discovered in 1896 by Henri Becquerel. Research by Otto Hahn, Lise Meitner, Enrico Fermi and others (including J. Robert Oppenheimer), beginning in 1934, led to its use as a fuel in the nuclear power industry and in Little Boy, the first nuclear weapon used in war. An ensuing arms race during the Cold War between the United States and the Soviet Union produced tens of thousands of nuclear weapons that used uranium metal and uranium-derived plutonium-239. Dismantling of these weapons and related nuclear facilities is carried out within various nuclear disarmament programs and costs billions of dollars.

Sources: en.wikipedia.org

Supporting material

== Research == Ala-Kokko's research focuses on collagen in cartilage, and connective tissue disorders. She has, with her research group, succeeded in identifying the errors in cartilage collagen that lead to the development of osteoarthritis and diseases of the vertebrae, amongst others. Her results have assisted in the diagnosis and care of patients, as well as improvements to the way in which these diseases are treated. She has published about 160 articles based on her research, and she has been awarded five patents.

=== Multimodal therapy === Despite the extensive investigation into single therapeutic targets for cachexia, the most effective treatments use multi-targeted therapies. In Europe, a combination of non-drug approaches including physical training, nutritional counseling, and psychotherapeutic intervention are used in belief this approach may be more effective than monotherapy. Administration of anti-inflammatory drugs showed efficacy and safety in the treatment of people with advanced cancer cachexia.

Ultimately a very low-calorie, ketogenic diet (of 5% carbohydrate) "was not associated with significant loss of fat mass" compared to a non-specialized diet with the same calories; there was no useful "metabolic advantage". In 2017, Kevin Hall, a National Institutes of Health researcher hired to assist with the project, wrote that the carbohydrate-insulin hypothesis had been falsified by experiment. Hall wrote "the rise in obesity prevalence may be primarily due to increased consumption of refined carbohydrates, but the mechanisms are likely to be quite different from those proposed by the carbohydrate–insulin model."

In many East Asian countries, double-eyelid surgery is the most popular surgery, especially in South Korea. Depending on the methods, directing doctors' experience and the difficulty of the individual case, this surgery can cost between about US$2,000 to $4,000. The procedure is famous for producing double-eyelid for patients for the long term. This kind of operation normally takes about thirty minutes to an hour, and patients are not required to stay hospitalized afterward. Stitches are removed five to seven days after surgery. Many foreigners go to South Korea each year for blepharoplasty.

Sources: en.wikipedia.org

Supporting material

=== 19th century === Apparently unaware of Smeaton's work, the same principle was identified by Frenchman Louis Vicat in the first decade of the nineteenth century. Vicat went on to devise a method of combining chalk and clay into an intimate mixture, and, burning this, produced an "artificial cement" in 1817 considered the "principal forerunner" of Portland cement and "...Edgar Dobbs of Southwark patented a cement of this kind in 1811." In Russia, Egor Cheliev created a new binder by mixing lime and clay. His results were published in 1822 in his book A Treatise on the Art to Prepare a Good Mortar published in St. Petersburg. A few years later in 1825, he published another book, which described various methods of making cement and concrete, and the benefits of cement in the construction of buildings and embankments.

Many lichens disperse via symbiotic vegetative propagules such as soredia, isidia, or blastidia, but X. parietina lacks these structures and must re-establish its symbiotic state with each reproductive cycle. Instead, oribatid mites—Trhypochtonius tectorum and Trichoribates trimaculatus—serve as vectors, consuming X. parietina and dispersing its viable ascospores and photobiont cells through their faecal pellets. This facilitates both short- and long-distance dispersal. Despite lacking specialized vegetative propagules, X. parietina demonstrates sophisticated reproductive strategies that overcome the challenges of sexual reproduction in lichens. When germinating fungal spores spread across a substrate, they first form associations with common non-symbiotic algae (such as Pleurococcus), creating a preliminary "proto-lichen" stage. This widespread network increases the likelihood of encountering the Trebouxioid photobiont needed for proper thallus development. Additionally, the mycobiont can extract suitable algal partners from the soredia of other lichens, particularly Physcia species that often grow alongside X. parietina and contain compatible photobionts. Once contact is established with compatible Trebouxia cells, the mycobiont forms specialized structures called haustorial complexes that enable efficient nutrient exchange.

=== Scientific consultation === Verdine is a member of both the Board of Scientific Consultants of the Memorial Sloan-Kettering Cancer Center, the Board of Scientific Advisors of the National Cancer Institute, Advisory Board at Spinal Muscular Atrophy Foundation, and the Board of Reviewers at Bill & Melinda Gates Foundation.

Mg2+ is first enabled to bind to the active site by the rotation of His335 to an alternate conformation. Mg2+ is then coordinated by the His residues of the active site (His300, His302, His335), and is partially neutralized by the coordination of three water molecules and their conversion to −OH. This coordination results in an unstable complex, but produces a favorable environment for the binding of Mg2+. Formation of the carbamate is favored by an alkaline pH. The pH and the concentration of magnesium ions in the fluid compartment (in plants, the stroma of the chloroplast) increases in the light. The role of changing pH and magnesium ion levels in the regulation of RuBisCO enzyme activity is discussed below. Once the carbamate is formed, His335 finalizes the activation by returning to its initial position through thermal fluctuation.

=== 24 March === A representative of the Indian Air Force told the Indian parliament that a "major delivery" from Russia was not going to proceed due to the war with Ukraine. This was the first time that a government officially acknowledged shortcomings by Russia to supply weapons or components due to the ongoing war in Ukraine.

Sources: en.wikipedia.org

Frequently asked questions

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.

How is SR9009 detected?

Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.

How should SR9009 be stored?

Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.

What is SR9009?

SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.

Network